Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Asset Writedowns and Impairment (2019 - 2021)

AVITA Medical posted quarterly Asset Writedowns and Impairment of $19000.0 for Q3 2021, up 124.68% year-on-year from $8456.6 in Q3 2020, and up 480.0% on a QoQ basis from -$5000.0 in Q4 2020.

AVITA Medical (RCEL) has 3 years of Asset Writedowns and Impairment data on file, last reported at $19000.0 in Q3 2021.

  • For the quarter ending Q3 2021, Asset Writedowns and Impairment rose 124.68% year-over-year to $19000.0; the trailing twelve-month figure through Dec 2023 stood at $14000.0 (changed N/A YoY), and the FY2023 full-year result was $4000.0, changed N/A from the prior year.
  • Asset Writedowns and Impairment for Q3 2021 stood at $19000.0, up from -$5000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $19000.0 in Q3 2021 and bottomed at -$77000.0 in Q3 2020.
  • The 3-year median for Asset Writedowns and Impairment is $8000.0 (2019), against an average of -$8800.0.
  • The widest annual swing landed in 2020, when Asset Writedowns and Impairment tumbled 1062.5%; it then jumped 124.68% in 2021.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $11000.0 in 2019, then tumbled by 145.45% to -$5000.0 in 2020, then surged by 480.0% to $19000.0 in 2021.
  • The last three Asset Writedowns and Impairment figures came in at $19000.0 (Q3 2021), -$5000.0 (Q4 2020), and -$77000.0 (Q3 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 AVITA Medical 121.89 Mn 103.71 Mn 14.31 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2021 19,000.00
Sep 30, 2021 19,000.00
Dec 31, 2020 -5,000.00
Dec 31, 2020 -5,000.00
Sep 30, 2020 -77,000.00
Sep 30, 2020 -77,000.00
Dec 31, 2019 11,000.00
Dec 31, 2019 11,000.00
Sep 30, 2019 8,000.00
Sep 30, 2019 8,000.00